Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Pipeline Review, H2 2016

Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Pipeline Review, H2 2016
Published Jul 30, 2016
44 pages — Published Jul 30, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Pipeline Review, H2 2016, provides in depth analysis on Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) targeted pipeline therapeutics.

The report provides comprehensive information on the Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP)
- The report reviews Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) targeted therapeutics and enlists all their major and minor projects
- The report assesses Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies&

  
Source:
Document ID
GMDHC0424TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
Introduction51
  Global Markets Direct Report Coverage51
Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) Overview61
Therapeutics Development73
  Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) Products under Development by Stage of Development71
  Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) Products under Development by Therapy Area81
  Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) Products under Development by Indication91
Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) Pipeline Products Glance102
  Late Stage Products101
  Early Stage Products111
Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) Products under Development by Companies122
Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) Therapeutics Assessment146
  Assessment by Monotherapy/Combination Products141
  Assessment by Mechanism of Action151
  Assessment by Route of Administration162
  Assessment by Molecule Type182
Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) Companies Involved in Therapeutics Development202
  Noxxon Pharma AG201
  Pieris Pharmaceuticals, Inc.211
Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) Drug Profiles229
  lexaptepid pegol Drug Profile223
  M-009 Drug Profile251
  M-012 Drug Profile262
  PRS-080 Drug Profile282
  Recombinant Protein for Iron Overload Disorders Drug Profile301
Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) Dormant Projects311
Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) Discontinued Products321
Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) Featured News &Press Releases3310
  May 09, 2016: Merganser Biotech Announces Issuance of U.S. Patent 9,315,545 Covering Development Compound M012331
  May 06, 2016: Drug-like Compound Shows Promise in Treating Two Blood Diseases331
  Feb 24, 2016: Merganser Biotech Initiates First Clinical Trial341
  Dec 07, 2015: Pieris Pharmaceuticals Presents Clinical Data for its Hepcidin Antagonist Program, PRS-080, at the 2015 American Society Of Hematology Annual Meeting341
  Nov 05, 2015: Pieris Pharmaceuticals Announces Presentation Of Clinical Data For Its Hepcidin Antagonist Program, Prs-080, At The 2015 American Society Of Hematology Annual Meeting351
  Jun 10, 2015: Pieris Pharmaceuticals Completes Dosing of Healthy Volunteers in Phase I Clinical Trial for Anticalin Program in Anemia361
  Dec 11, 2014: Pieris Initiates Phase I Clinical Trial for Anticalin to Treat Anemia361
  Jul 31, 2014: NOXXON Pharma Initiates Phase IIa Study Of Anti-Hepcidin Spiegelmer Lexaptepid Pegol (NOX-H94) In Dialysis Patients With EPO-hypo-responsive Anemia371
  Apr 08, 2014: Anti-Hepcidin Spiegelmer Lexaptepid Pegol Increases Hemoglobin in Subset of Anemic Patients in Pilot Phase IIa Study371
  Dec 06, 2012: Noxxon Pharma To Present Phase I Data Of NOX-H94 At ASH Annual Meeting 2012381
  Dec 04, 2012: Noxxon Pharma Initiates Phase IIa Clinical Trial Of Anti-hepcidin Spiegelmer NOX-H94381
  Dec 13, 2011: Pieris Presents Preclinical Data For PRS-080 Hepcidin Antagonist Anticalin Program At ASH Annual Meeting391
  Nov 01, 2011: UCLA scientists design experimental treatment for iron-overload diseases401
  Sep 06, 2011: NOXXON Initiates Phase I Clinical Trial Of NOX-H94 For Anemia Of Chronic Disease411
  May 23, 2011: Pieris Announces Preclinical In Vitro And In Vivo Data For Anticalin PRS-080 Hepcidin Antagonist Drug Program421
Appendix432
  Methodology431
  Coverage431
  Secondary Research431
  Primary Research431
  Expert Panel Validation431
  Contact Us431
  Disclaimer441

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Pipeline Review, H2 2016" Jul 30, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Hepcidin-Liver-Expressed-Antimicrobial-Peptide-1-or-Putative-Liver-Tumor-Regressor-or-HAMP-Pipeline-Review-H2-2016-2088-16322>
  
APA:
Global Markets Direct - Market Research. (2016). Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Pipeline Review, H2 2016 Jul 30, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Hepcidin-Liver-Expressed-Antimicrobial-Peptide-1-or-Putative-Liver-Tumor-Regressor-or-HAMP-Pipeline-Review-H2-2016-2088-16322>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.